

Haematologica
HAEMATOL/2017/171041
Version 3

Characterization of atrial fibrillation adverse events reported in ibrutinib
randomized controlled registration trials

Jennifer R. Brown, Javid Moslehi, Susan O' Brien, Paolo Ghia, Peter Hillmen, Florence Cymbalista, Tait D. Shanafelt, Graeme Fraser, Simon Rule, Thomas J. Kipps, Steven Coutre, Marie-Sarah Dilhuydy, Paula Cramer, Alessandra Tedeschi, Ulrich Jaeger, Martin Dreyling, John C. Byrd, Angela Howes, Michael Todd, Jessica Vermeulen, Danelle F. James, Fong Clow, Lori Styles, Rudy Valentino, Mark Wildgust, Michelle Mahler, and Jan A. Burger

Disclosures: JRB: Consultancy: Janssen, Pharmacyclics, Celgene, Genentech/Roche, Gilead, Infinity, Astra-Zeneca, AbbVie. JM: Consultancy: Novartis, Pfizer, BMS, Takeda/Millennium/Ariad, Acceleron, Vertex, Incyte, Rgenix, Verastem, Pharmacyclics, AbbVie/Abbot, Janssen, Onyx/Amgen, Deciphera, Alnylam, CardioOnc. SO: Consultancy and research funding: Pharmacyclics; Consultancy and honoraria: Janssen. PG: Consultancy: Adaptive, Pharmacyclics, Gilead, GSK, AbbVie, Janssen, Roche, Acerta Pharma BV. PH: Consultancy: Janssen; Honoraria and research funding: Janssen, AbbVie, Roche, Novartis, Pharmacyclics, Gilead; Research funding: Celgene. FC: Honoraria: Gilead, Roche, AbbVie, Janssen; Research funding: Janssen. TDF: Research funding: GSK, Pharmacyclics, Celgene, Genentech, Cephalon, Janssen, Hospira, Polyphenon E International. GF: Consultancy: Roche; Honoraria and research funding: Janssen, Celgene; Speakers bureau: Janssen; Honoraria: Lundbeck. SR: Consultancy: Roche, Janssen, Celgene, Gilead; Travel grants: Roche, Janssen; Research funding: Janssen, Celgene. TJK: Consultancy and honoraria: Gilead, Pharmacyclics, Celgene, Roche, AbbVie; Research funding: Celgene, Roche, AbbVie. SEC: Research funding: Acerta; Consultancy and research funding: Gilead, Pharmacyclics, AbbVie, Janssen, Celgene. M-SD: Honoraria: Roche, Janssen, Gilead; Travel grants: Roche, Janssen; Speakers bureau: Janssen, Gilead. PC: Travel grants: Roche, Gilead, Janssen Cilag, Astellas, Mundipharma; Research funding: Roche, Gilead, GSK, Novartis, Janssen Cilag; Honoraria: Roche, Janssen Cilag; Advisory boards: Janssen Cilag, Novartis, AstraZeneca. AT: Consultancy, travel grants and honoraria: Janssen, Gilead. UJ: Research funding: Janssen. MHD: Honoraria, advisory boards, travel grants, speakers bureau: Janssen. JCB: No competing financial interests to declare. AH: Employment: Janssen. MT: Consultancy: Janssen. JV: Employment: Janssen. DJ: Employment: Pharmacyclics. FC: Employment: Pharmacyclics. LS: Employment: Pharmacyclics. RV: Employment: Pharmacyclics. MW: Employment: Janssen. MM: Employment: Janssen. JAB: Consultancy: Novartis, Gilead, Janssen, Abbott; Research funding: Gilead, Pharmacyclics, Portola, Celgene, Noxxon.

Contributions: All authors contributed to the study concept, data collection or data interpretation, and to drafting, revising, and approval of the manuscript.